Regeneron Pharmaceuticals, Inc. plans to purchase Sanofi’s stake in the Regeneron and Sanofi collaboration on Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization and manufacturing rights to the medicine. The transaction is subject to merger control clearance outside the U.S. and is expected to close 3Q22. Once closed, Regeneron will record 100% of global sales and expenses for the Libtayo program.   Libtayo, which was invented using Regeneron...